Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with hematological malignancies: A preliminary report

Pediatric Hematology and Oncology

Volumn 21, Issue 2, 2004, Pages 145-156

  El Sayed, Manal H ^a   Shanab, Gamila ^b   Karim, Amr M ^b   El Tawil, Ahmed ^c   Black, Andy ^d   Dixon, Jonathan S ^d  

^a Ain Shams University   (Egypt)

^b Ain Shams University   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

HBV reactivation; Hematological malignancies; Lamivudine; Paediatrics

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHOTREXATE; PREDNISONE; VINCRISTINE; VINCRISTINE SULFATE; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CHILD; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HISTOLOGY; HUMAN; IMMUNE DEFICIENCY; MALE; SEROCONVERSION; VIRUS REACTIVATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG SYNERGISM; FEMALE; HEMATOLOGIC NEOPLASMS; HEPATITIS B; HUMANS; IMMUNOSUPPRESSION; LAMIVUDINE; MALE; REMISSION INDUCTION; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 1542289832     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010490273019     Document Type: Article

References (30)

1. Lau JYN, Lai CL, Lin HJ, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. QJ Med. 1989;73(270):911-917.
2. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B-virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology. 1991;100:182-188.
3. Soh LT, Ang PT, Sng I, et al. Fulminant hepatic failure in non-Hodgkin's lymphoma patients treated with chemotherapy. Eur J Cancer. 1992;28A:1338-1339.
4. Scullard GH, Smith CI, Merigaan TC, et al. Effects in immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology. 1982;81:987-991.
5. Davis GL, Hoofnagle JH. Reactivation of chronic hepatitis B virus infection. Gastroenterology. 1987;92: 2028-2031.
6. Saif MW, Little RF, Hamilton JM, et al. Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of literature. Ann Oncol. 2001;12:123-129.
7. El-Sayed MH, Mohamed MM, Karim A, et al. Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies. Hematol J. 2003;4:321-327.
8. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-1263.
9. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61-68.
10. Lai CL, Ching CK, Tung AK, Li E, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology. 1997;25:241-244.
11. Clark FL, Drummond MV, Chambers S, et al. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade none-Hodgkin's lymphoma. Ann Oncol. 1998;9:385-387.
12. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34:1225-1241.
13. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
14. Yokosuka O, Tagawa M, Omata M. PCR detection of hepatitis B virus. In: Persing DH, Smith TF, Tenover FC, White TJ, eds. Diagnostic Molecular Microbiology: Principles and Applications. Washington DC: American Society for Microbiology; 1993:322-326.
15. Carman WF, Kidd AH. An assessment of optimal conditions of amplification of HIV cDNA using Thermus aquatics polymerase. J Virol Method. 1989;23:277-289.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
17. Lazizi Y, El-Fassi E, Pillot J. Detection of hepatitis C virus sequences in sera with controversial serology by nested polymerase chain reaction. J Clin Microbiol. 1992;30:931-934.
18. Sevinir B, Meral A, Gunay U, Ozkan T, Ozuysal S, Sinirtas M. Increased risk of chronic hepatitis in children with cancer. Med Pediatr Oncol. 2003;40:104-110.
19. Yeo W, Steinberg JL, Tam JS, et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol. 1999;59:263-269.
20. Igarashi T, Niitsuma H, Nagasaki F, et al. Lamivudine treatment for hepatitis B virus carriers receiving chemotherapy and immunosuppressive therapy. Jpn Pharmacol Therap. 2001;29:363-369.
21. Kawai Y, Ikegaya S, Hata M, et al. Successful lamivudine therapy for postchemotherapeutic fulminant hepatitis B in a hepatitis B virus carrier with non-Hodgkin's lymphoma: case report and review of the literature. Ann Hematol. 2001;80:482-484.
22. Rossi G, Pelizzari A, Motta M, et al. Primary prophylaxis with lamivudine of hepatitis B virus (HBV) reactivation in HBsAg-positive patients undergoing chemotherapy for hematologic malignancies. Blood. 2000;96:A86.
23. Silvestri F, Ermacora A, Sperotto A, et al. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol. 2000;108:394-396.
24. Endo T, Sakai T, Fujimoto K, et al. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2001;27:433-436.
25. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299-307.
26. Jonas MM, Kelley DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002;346:1706-1713.
27. Fontana RJ, Hann HW, Wright T, et al. Lamivudine Compassionate Use Study Group. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl. 2001;7:511-512.
28. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother. 2001;12(Suppl 1):67-71.
29. Suzuki Y, Kumada H, Ikeda K. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol. 1999;30:743-748.
30. Kweon YO, Goodman ZD, Dienstag JL, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol. 2001;35:749-755.